Product partnering
We are an experienced RNA technology company dedicated to professionally partnering with pharma and biotech with an emerging or established interest in RNA therapeutics. Our expert team supports start-up, early stage and late-stage projects by using our proprietary platforms across RNA chemistry, LNP formulation, and Process Technology, to drive new pipeline development or resolve manufacturing challenges for our partners.
![etherna image](https://www.etherna.be/wp-content/uploads/2023/09/mRNA_adjuvants_image.png)
mRNA adjuvants
TriMix and TetraMix are proprietary combinations of mRNAs encoding for immune stimulatory proteins that optimally activate dendritic cells to induce vaccine-specific T cells. As such, TriMix and TetraMix can be used to:
- Enhance efficacy of T-cell vaccines
- Improve the ex vivo expansion of antigen-specific T cells using TriMix or TetraMix-transfected dendritic cells.
![](https://www.etherna.be/wp-content/uploads/2023/09/Tech_MRNA_Icon_1.png)
Flexible partnership
- Support from design, candidate designation, clinical development to regulatory approval
- From single indications to
comprehensive pipeline development
![](https://www.etherna.be/wp-content/uploads/2023/09/Tech_MRNA_Icon_1.png)
Expert development
- Dedicated teams committed to meeting your project deadlines
- Seamless transition through all
development stages
![](https://www.etherna.be/wp-content/uploads/2023/09/Tech_MRNA_Icon_1.png)
Integrated offering
- In-house in-depth chemistry, formulation and manufacturing expertise
- Single resource for accelerated delivery, no need for multiple partners
To drive discovery and solve challenges for our partners, enabling them to deliver cost-effective,
differentiated, and efficacious RNA therapeutics.
“I’m very happy to let you know that the FDA informed us that our IND was cleared! We do expect non-hold questions in the next few weeks. We thank you so much for your great contribution!”
Versameb“etherna’s eGFP gives 3x higher expression than all others previously tested”
Karolinska Institute“I am writing to you following the experiments we performed using the GFP mRNA received from eTheRNA….. we found it to be an excellent cargo in-vitro in comparison to others”
Dan Peer“….we have now conducted our investigational experiments and I can confirm that your mRNA performed wonderfully!”
Resolution Tx“…we are very confident on ETheRNA performance. All good so far!”
Scripps“…It has certainly been a very pleasant experience so far…”
Diosynvax“I have very much enjoyed working with the team at eTheRNA. I’ve been impressed with the quality of the work and the responsiveness of the team” – etherna’s mRNA is superior to that of Aldevron
HDT BioContact us with any queries or for pricing information.